Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.46 |
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CTSL | P07711 | 10/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624295 | 0.92 | CTSL (0.48) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL13624335 | 0.87 | CTSL (0.54) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL13624339 | 0.85 | CTSK (0.53) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13624338 | 0.82 | CTSL (0.46) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL13624340 | 0.82 | CTSS (0.45) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL4366149 | 0.79 | CTSL (0.53) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL13624300 | 0.79 | CTSL (0.51) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL13624298 | 0.78 | CTSL (0.51) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL13624307 | 0.78 | CTSK (0.48) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL13624418 | 0.77 | CTSL (0.57) | CTSSCTSKCTSLCTSBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSS 5/4885CTSK 15/4885CTSL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.